Wave of FDA Warning Letters to Injectable Compounders in Q1 2014 Follows 2013 Inspection Blitz and Legislative Empowerment; Reci FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP 1s BioSpace of the Federal Food, Drug, and Cosmetic Act (FDCA).* The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA Moves on Peptides: What Compounding Pharmacies Need to Know